Sibeprenlimab
Product Specifications
UNSPSC Description
Sibeprenlimab (VIS649) is a humanized IgG2 monoclonal antibody which inhibits a proliferation-inducing ligand (APRIL). Sibeprenlimab suppresses pathogenic immunoglobulins (IgA and IgM), while preserving antibody responses to mRNA-based vaccines against SARS-COV-2. Sibeprenlimab reduces urinary protein-to-creatinine ratio (UPCR) and glomerular filtration rate (GFR). Sibeprenlimab is promising for the research of IgA nephropathy (IgAN)[1][2][3].
Target Antigen
SARS-CoV
Type
Inhibitory Antibodies
Related Pathways
Anti-infection
Applications
Cancer-programmed cell death
Field of Research
Cancer; Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/sibeprenlimab.html
Purity
99.77
Solubility
10 mM in DMSO
Smiles
[Sibeprenlimab]
References & Citations
[1]Mohit Mathur, et al. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VIS649 (Sibeprenlimab), an APRIL-Neutralizing IgG2 Monoclonal Antibody, in Healthy Volunteers. Kidney Int Rep. 2022 Feb 8;7(5):993-1003. |[2]Mathur M, et al. A PRoliferation-Inducing Ligand (APRIL) in the Pathogenesis of Immunoglobulin A Nephropathy: A Review of the Evidence. J Clin Med. 2023 Nov 4;12(21):6927. |[3]Refardt J, et al. Arginine or Hypertonic Saline-Stimulated Copeptin to Diagnose AVP Deficiency. N Engl J Med. 2023 Nov 16;389(20):1877-1887.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Product Datasheet
http://file.medchemexpress.com/batch_PDF/HY-P99901/Sibeprenlimab-DataSheet-MedChemExpress.pdf
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-P99901/Sibeprenlimab-SDS-MedChemExpress.pdf
Clinical Information
Phase 3
CAS Number
2382896-07-1
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
